Epidithiodioxopiperazine Composition for Metastatic Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for solid cancers, such as surgery, radiation therapy, and chemotherapy, are limited in efficacy and specificity, particularly for cancers that metastasize and are not confined to a specific site, necessitating the development of small-molecule compounds that can inhibit growth and metastasis of breast, lung, stomach, skin, colon, and pancreatic cancers.
Innovation Solution
A pharmaceutical composition comprising epidithiodioxopiperazine derivatives with an intramolecular disulfide bridge, either natural or synthetic, is used to inhibit the growth and metastasis of solid cancers by mimicking the intracellular activity of Prxll, targeting cancer cells with low or no expression of peroxyredoxins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (surgery, radiation therapy, chemotherapy) are used for solid cancer, then treatment coverage is provided, but efficacy and specificity are limited
Solution Approach 1:
The patent modifies the chemical structure by introducing specific substituents (R1-R4 groups) at positions 5 and 7 of the epidithiodioxopiperazine ring, changing molecular parameters to achieve selective targeting of cancer cells with low peroxyredoxin expression while improving treatment efficacy across multiple cancer types
Solution Approach 2:
The invention targets specific local characteristics of cancer cells (low or no expression of peroxyredoxins) rather than treating all cells uniformly, enabling selective inhibition of cancer cell growth and metastasis while preserving normal cell function
2Reliability
If natural epidithiodioxopiperazine derivatives are used, then antitumor activity is achieved, but synthetic derivatives with improved properties are needed
Solution Approach 1:
The patent creates synthetic copies of natural epidithiodioxopiperazine derivatives (gliotoxin, chetomin) with modified structures, replicating the core antitumor mechanism while improving manufacturability and allowing systematic optimization of therapeutic properties
Solution Approach 2:
By systematically varying substituent parameters (R1-R4 groups including alkyl, alkenyl, alkynyl, alkoxy-aryl-C1-6-alkyl, and heteroaryl-C5-10-yl groups), the invention optimizes both antitumor activity and synthetic accessibility, creating a series of derivatizable compounds
Data Source
Figure 1A~1C
Figure 2A~2K
Figure 3
AI summary
The present invention relates to a pharmaceutical composition for prevention or treatment of solid cancer comprising an epidithiodioxopiperazine derivative compound based on a parent structure comprising an intramolecular disulfide bridge in an epidithiodioxopiperazine ring or a pharmaceutically acceptable salt thereof as an active ingredient.